References:1. Breo Ellipta Data Sheet, GSK New Zealand, available at www.medsafe.govt.nz 2. Breo Ellipta Consumer Medical Information, GSK New Zealand, available at www.medsafe.govt.nz 3. Anoro Ellipta Data Sheet, GSK New Zealand, available at www.medsafe.govt.nz 4. Anoro Ellipta Consumer Medical Information, GSK New Zealand, available at www.medsafe.govt.nz
Anoro® Ellipta® (umeclidinium bromide/vilanterol trifenatate inhaler 62.5/25mcg per inhalation) is a Prescription Medicine. Anoro Ellipta is indicated as a long-term maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD). Anoro Ellipta is a fully funded medicine; Special Authority criteria apply. Maximum Daily Dose: One inhalation once daily. Contraindications: Patients with severe milk-protein allergy or those who have hypersensitivity to umeclidinium, vilanterol or any excipients. Side Effects: Nasopharyngitis, oropharyngeal pain, sinusitis, pharyngitis, cough, urinary tract infection, constipation, dry mouth, hypertension, upper respiratory tract infections. Warnings and Precautions: Not recommended for use in patients with asthma or for relief of acute symptoms or an acute exacerbation. Use care when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole), beta-blockers and in patients with severe cardiovascular disease, narrow-angle glaucoma or urinary retention. Before prescribing Anoro Ellipta, please review the Data Sheet at www.medsafe.govt.nz.
TAPS NA12164 PM-NZ-UCV-WCNT-20AUG0004
Breo® Ellipta® (fluticasone furoate/vilanterol trifenatate puffer 100/25mcg per inhalation) is a Prescription Medicine. Breo Ellipta is used for the regular treatment of asthma (12 years of age and older) and for adults with Chronic Obstructive Pulmonary Disease (COPD). Breo Ellipta 100/25mcg is a fully funded medicine; Breo Ellipta 200/25mcg is a private purchase medicine (dose indicated in asthma only). Use strictly as directed. Breo Ellipta is not for relief of acute symptoms; a separate reliever puffer may be required. Always carry your reliever puffer. Do not discontinue Breo Ellipta abruptly. This medicine has risks and benefits. Tell your doctor: If you are taking any other medicines or herbal remedies, you have liver disease, heart problems, high blood pressure, pulmonary tuberculosis (TB), infection of the lungs (pneumonia) or weak bones (oesteoporosis). Side Effects: Headache, common cold, oral thrush, infection of the nose sinuses or throat, flu (influenza), pain and irritation at the back of the mouth and throat, inflammation of the sinuses, pneumonia (in patients with COPD) and weakening of the bones, leading to fractures. If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional. For more information see Breo Ellipta Consumer Medicine Information at www.medsafe.govt.nz. Normal doctor’s charges apply. Ask your doctor if Breo Ellipta is right for you.
Breo, Anoro and Ellipta are registered trade marks of the GlaxoSmithKline group of companies. Breo Ellipta and Anoro Ellipta were developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
